TCR gene therapy of spontaneous prostate carcinoma requires in vivo T cell activation

Moniek A. De Witte, Gavin M. Bendle, Marly D. Van Den Boom, Miriam Coccoris, Todd D. Schell, Satvir S. Tevethia, Harm Van Tinteren, Elly M. Mesman, Ji Ying Song, Ton N.M. Schumacher

Research output: Contribution to journalArticlepeer-review

40 Citations (Scopus)


Analogous to the clinical use of recombinant high-affinity Abs, transfer of TCR genes may be used to create a T cell compartment specific for self-Ags to which the endogenous T cell repertoire is immune tolerant. In this study, we show in a spontaneous prostate carcinoma model that the combination of vaccination with adoptive transfer of small numbers of T cells that are genetically modified with a tumor-specific TCR results in a marked suppression of tumor development, even though both treatments are by themselves without effect. These results demonstrate the value of TCR gene transfer to target otherwise nonimmunogenic tumor-associated self-Ags provided that adoptive transfer occurs under conditions that allow in vivo expansion of the TCR-modified T cells.

Original languageEnglish
Pages (from-to)2563-2571
Number of pages9
JournalJournal of Immunology
Issue number4
Publication statusPublished - 15 Aug 2008
Externally publishedYes


Dive into the research topics of 'TCR gene therapy of spontaneous prostate carcinoma requires in vivo T cell activation'. Together they form a unique fingerprint.

Cite this